Search company, investor...

About Molecular Oncology

Molecular Oncology highlights new discoveries, approaches, as well as technical developments, in basic, clinical and discovery-driven translational research. See About Molecular Oncology for a longer list of topics covered.

Headquarters Location

Danish Cancer Society 49 DK

2100 Strandboulevarden,

Denmark

800-654-2452

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo
You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together.
Click Now. Join a live demo
Join a demo

Latest Molecular Oncology News

QIAGEN : Acquires N-of-One, Expanding Its Clinical Bioinformatics Capabilities in Molecular Oncology Decision Support

Jan 7, 2019

0 Message : *Required fields Enhancing QIAGEN’s industry-leading position with access to MarkerMine™ database and real-world evidence insights that provide insights for targeted therapy options QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today it has entered into an agreement to acquire N-of-One, Inc., a privately-held U.S. molecular decision support company and pioneer in clinical interpretation services for complex genomic data. The addition of N-of-One will enable QIAGEN to significantly expand its decision-support solutions while offering a broader range of software, content and service-based solutions. It will also enable QIAGEN to provide customers with greater access to valuable genomic data assets and service offerings. N-of-One’s technology-enabled, yet human-driven, services and the proprietary MarkerMine™ database are planned to be integrated into QIAGEN Clinical Insight (QCI), enhancing this industry-leading clinical offering with medical interpretation and real-world evidence insights and offering robust decision support in oncology. The proprietary database, services and processes of N-of-One produce case-specific reports based on data generated with molecular tests, including next-generation sequencing (NGS) technologies, and deliver clinical evidence for biomarkers and a list of therapeutic options for consideration. N-of-One also provides patient-specific clinical trial matching services and a somatic cancer database with more than 125,000 anonymized patient samples. This data will be added to the patient samples currently available in QCI, further increasing QIAGEN’s position in offering by far the largest genomics knowledge base. Please find the full press release here View source version on businesswire.com: https://www.businesswire.com/news/home/20190106005121/en/ © Business Wire 2019

Molecular Oncology Frequently Asked Questions (FAQ)

    CB Insights
    Looking for a leg up on competitive, customer and technology insights?
    CB Insights puts confidence and clarity into your most strategic decisions.
    See how. Join a demo.
    Join a demo
    Trusted by the world's smartest companies to:
    • Predict emerging trends
    • See competitors' playbooks
    • Stalk the smart money
    • Identify tomorrow's challengers
    • Spot growing industries
    • Kill analyst data work
    Let's see how we can help you!
    MicrosoftWalmartWells Fargo

    Discover the right solution for your team

    The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

    Join a demo

    CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.